Pneumococcal polysaccharide vaccine has been licensed for use in the United States for>
30 years, and two-thirds of the elderly population in the United States have received this …

Streptococcus pneumoniae causes considerable morbidity and mortality in the elderly.
There are three established approaches to pneumococcal vaccination: polysaccharide …

The effective prevention of Streptococcus pneumoniae infection has a renewed priority in an
era in which the emergence of antibacterial-resistant strains has the potential to further …

Invasive pneumococcal disease continues to be important problem for older adults.
Pneumococcal polysaccharide vaccine (PPV23) has a clinical effectiveness of 43–81%, and …

ContextA conjugate vaccine targeting 7 pneumococcal serotypes was licensed for young
children in 2000. In contrast to the 23-valent polysaccharide vaccine used in adults, the 7 …

We compared the hypothetical effects of the 23-valent polysaccharide pneumococcal
vaccine with new vaccines on preventing invasive and noninvasive pneumococcal disease …

Streptococcus pneumoniae remains a major cause of morbidity and mortality throughout the
world. To date, after the introduction of routine childhood immunization, elderly people (ie …

As individuals advance in age, the risk of infection, bacteremia, and mortality caused by
Streptococcus pneumoniae rises. Retrospective data demonstrate that the licensed …

During the 20 years following its licensure, pneumococcal vaccine has not been widely
used. Although the vaccine was shown to be efficacious in South African gold miners …

There are many challenges in preventing and managing community-acquired pneumonia in
the elderly. S. pneumoniae remains the most important cause. The clinical presentation of …